Literature DB >> 28349893

Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA-29b in meningioma.

Salim Katar1, Oguz Baran2, Sevket Evran3, Serdar Cevik3, Enes Akkaya3, Gozde Baran4, Veysel Antar1, Hakan Hanimoglu5, Mehmet Yasar Kaynar5.   

Abstract

OBJECTIVE: Meningiomas are among the most common intracranial tumors, accounting for 30% of all tumors of the central nervous system. Recent studies analyzing microRNA (miRNA) profiles and functions in cancer have provided valuable information about the molecular pathogenesis of several tumor types, including glioblastoma multiforme (GBM), hepatocellular carcinoma, and breast, lung, colon, and prostate cancer. miRNAs are a family of small, endogenous, noncoding RNAs of 18-25 nucleotides. In this study, we carried out a genome-wide array screen comparing miRNA-21, miRNA-107, miRNA-137 and miRNA-29b expression in meningiomas. PATIENTS AND METHODS: A total of 50 meningioma patients (16 men and 34 women) aged between 32 and 80 years were included. The study was conducted at Istanbul Research and Training Hospital Neurosurgery Clinic.
RESULTS: Our results have shown a significant increase in miRNA-21 expression with increasing histopathologic grade, while there was a significant reduction in miRNA-107 expression with the increasing histopathological grade. miRNA-137 and miRNA-29b expression did not differ significantly according to histopathologic grade.
CONCLUSION: The subject of our study, i.e. the association between miRNA expression and meningioma, is continuously gaining more importance in the wider context of the recent developments in genetic treatments.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Meningioma; miRNA-107; miRNA-137; miRNA-21; miRNA-29b

Mesh:

Substances:

Year:  2017        PMID: 28349893     DOI: 10.1016/j.clineuro.2017.03.016

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  7 in total

1.  Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapies.

Authors:  Ahmad A Nazem; Jacob Ruzevick; Manuel J Ferreira
Journal:  Oncotarget       Date:  2020-12-08

2.  Circulating Exosomal MiR-107 Restrains Tumorigenesis in Diffuse Large B-Cell Lymphoma by Targeting 14-3-3η.

Authors:  Jiarui Liu; Yang Han; Shunfeng Hu; Yiqing Cai; Juan Yang; Shuai Ren; Yi Zhao; Tiange Lu; Xiangxiang Zhou; Xin Wang
Journal:  Front Cell Dev Biol       Date:  2021-04-27

Review 3.  The Emerging Role of Non-Coding RNAs in Pituitary Gland Tumors and Meningioma.

Authors:  Soudeh Ghafouri-Fard; Atefe Abak; Bashdar Mahmud Hussen; Mohammad Taheri; Guive Sharifi
Journal:  Cancers (Basel)       Date:  2021-11-28       Impact factor: 6.639

Review 4.  The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications.

Authors:  Stephanie M Robert; Shaurey Vetsa; Arushii Nadar; Sagar Vasandani; Mark W Youngblood; Evan Gorelick; Lan Jin; Neelan Marianayagam; E Zeynep Erson-Omay; Murat Günel; Jennifer Moliterno
Journal:  J Neurooncol       Date:  2021-11-30       Impact factor: 4.130

5.  let-7d suppresses proliferation and invasion and promotes apoptosis of meningioma by targeting AEG-1.

Authors:  Hui Li; Jianmin Zhao
Journal:  Onco Targets Ther       Date:  2017-10-06       Impact factor: 4.147

Review 6.  Multi-Omics Analysis in Initiation and Progression of Meningiomas: From Pathogenesis to Diagnosis.

Authors:  Jiachen Liu; Congcong Xia; Gaiqing Wang
Journal:  Front Oncol       Date:  2020-08-28       Impact factor: 6.244

7.  Screening key miRNAs and genes in prostate cancer by microarray analysis.

Authors:  Jianhui Wu; Xuemei Li; Fei Luo; Jun Yan; Kuo Yang
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.